News & Updates

The implementation of a coordinated, multifaceted intervention helps increase the prescription of three groups of evidence-based cardiopreventive therapies in adults with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease, according to a study.

The survival benefit derived from using immune checkpoint inhibitors (ICIs) is more evident in patients with advanced nonsmall cell lung cancer (NSCLC) who received first-line therapy, showed low neutrophil/lymphocyte ratio (NLR), and had no history of hormone use following initial treatment, suggests a recent study.

Oral gepotidacin, an investigational, first-in-class oral antibiotic with a novel mechanism of action, showed favourable signals for the treatment of uncomplicated urinary tract infections (uUTIs), according to the results of two phase III trials.

For patients with rheumatoid arthritis, a history of cardiovascular disease, gastrointestinal disease, or liver disease, as well as prior use of nonsteroidal anti-inflammatory drugs can contribute to an increased risk of relapse after methotrexate dose reduction, as suggested in a study.

For cancer patients with depression, treatment with a single dose of psilocybin appears to yield rapid and meaningful improvements in depressive symptoms, as shown in a phase II study.

Ten-day treatment with vonoprazan 20 mg twice/day plus amoxicillin 750 mg four times/day (VHA-dual) as a first-line therapy for Helicobacter pylori infection results in satisfactory eradication rate of >90 percent, fewer adverse events (AEs), and similar adherence when compared with bismuth quadruple therapy (B-quadruple), results of a study have shown.